The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Jounce Therapeutics, Inc.

24 Feb 2023 14:02

RNS Number : 0348R
Geode Capital Management LLC
24 February 2023
 

Ap27

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1. KEY INFORMATION

 

(a) Full name of discloser

Geode Capital Management, LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

Jounce Therapeutics, Inc.

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

(e) Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

February 23, 2023

(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. INTERESTS AND SHORT POSITIONS

 

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

 

Ap28

 

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

 

Class of relevant security (Note 3)

USD 0.001 Common

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

755,193

1.46

(2) Cash-settled derivatives

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

Total

755,193

1.46

 

All interests and all short positions should be disclosed.

 

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevantsecurity

Purchase/sale

Number ofsecurities

Price per unit (Note 5)

 

Ap29

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

Number of reference securities (Note 6)

Price per unit (Note 5)

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates (Note 6)

Exerciseprice per unit

Type e.g. American, Europeanetc.

Expiry date

Option moneypaid/ received per unit

 

 

(ii) Exercise

 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

 

Class of relevant security

Nature of dealing e.g. subscription, conversion, exercise

Details

Price per unit (if applicable) (Note 5)

 

 

 

 

 

Ap30

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 None

 

(c) Attachments

 

Is a Supplemental Form 8 attached?

NO

 

Date of disclosure

February 24, 2023

Contact name

Geode Compliance

gcm_compliance@geodecapital.com

Telephone number

(800)-777-6757

 

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ISEZZLFLXLLBBBF
Date   Source Headline
1st May 20247:04 amEQSRedx Pharma Plc Shares now trading on JP Jenkins
1st May 20247:00 amRNSCancellation - Redx Pharma Plc
30th Apr 20245:46 pmRNSShare Purchases by a PDMR
30th Apr 20247:00 amRNSShare Purchases by PDMR’s
29th Apr 20247:00 amRNSUpdate on AIM Delisting
22nd Apr 20245:45 pmRNSTR-1: Notification of major holdings
19th Apr 202412:18 pmRNSResult of GM, Cancellation of Admission to Trading
18th Apr 20247:00 amRNSShare Purchases by a Director
12th Apr 20247:00 amRNSShare Purchase by a Director
10th Apr 20247:00 amRNSUpdate on Broking Arrangements
8th Apr 20243:32 pmRNSTR-1: Notification of major holdings
2nd Apr 20247:00 amRNSProposed Cancellation of Admission to Trading
14th Mar 202411:27 amRNSResult of AGM
6th Mar 20247:00 amRNSRedx to Exhibit Three Posters at AACR
28th Feb 20247:00 amRNSFirst Participant Dosed in Phase 1 Trial of RXC008
26th Feb 20247:00 amRNSRedx to Present at Cowen Health Care Conference
23rd Feb 20247:00 amRNSNew Grant of Options
16th Feb 20244:50 pmRNSNotice of AGM
14th Feb 20247:00 amRNSStatement re Press Report
8th Feb 20241:02 pmRNSTR-1: Notification of major holdings
7th Feb 20247:00 amRNSRedx announces sale of KRAS inhibitor program
15th Dec 20237:00 amRNSFinal Audited Results for Year Ended 30 September
12th Dec 20237:00 amRNSNotice of Preliminary Results
9th Nov 20237:00 amRNSHoldings in Company
8th Nov 20231:58 pmRNSTR-1: Notification of major holdings
8th Nov 20231:55 pmRNSTR-1: Notification of major holdings
7th Nov 20238:10 amRNSAdmission of Subscription Shares and TVR
6th Nov 202311:22 amRNSResults of General Meeting
6th Nov 20237:00 amRNSRedx Unveils Preclinical Data from RXC009
30th Oct 20237:00 amRNSRedx to present preclinical data on RXC009 at ASN
18th Oct 20237:00 amRNSProposed Subscription to raise c.£14.1 million
22nd Aug 20237:00 amRNSDirectorate Change
21st Aug 20237:00 amRNSZelasudil granted FDA Orphan Drug Designation
10th Jul 20237:00 amRNSExtension to Termination of Convertible Loan Notes
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSNew Grant of Options
31st May 20237:00 amRNSRedx to present at Jefferies Healthcare Conference
17th May 20237:00 amRNSInterim Results for the Six Months Ended 31 March
12th May 20239:51 amRNSDiscovery of Pirtobrutinib Recognised with Plaque
11th May 20237:00 amRNSPresentation of RXC007 Preclinical Efficacy Data
10th May 20237:00 amRNSNotice of Interim Results
3rd May 20237:00 amRNSRedx to Present at Keystone Symposia
3rd Apr 20237:01 amRNSProposed Business Combination Formally Lapsed
3rd Apr 20237:00 amRNSTermination of Proposed Business Combination
30th Mar 20238:36 amRNSForm 8.5 (EPT/RI) - Redx Pharma plc
27th Mar 20232:06 pmRNSStatement Following Jounce Announcement
27th Mar 20232:00 pmRNSStatement re Merger Agreement
24th Mar 20232:31 pmRNSForm 8.3 - Jounce Therapeutics, Inc
22nd Mar 20232:20 pmRNSForm 8.3 - Jounce Therapeutics, Inc
20th Mar 20233:00 pmRNSForm 8.3 - Jounce Therapeutics, Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.